The LixiLan-L Trial: Consistent Findings in Glycemic Control, Body Weight, and Hypoglycemia With iGlarLixi Vs Insulin Glargine Across Baseline A1C, Body Mass Index, and Diabetes Duration

Date: 
April, 2017
April 6, 2017. This exploratory analysis was conducted to determine the impact of patient baseline characteristics on outcomes observed in the LixiLan-L randomized open-label trial (N=736). This 30-week trial evaluated the efficacy and safety of iGlarLixi (insulin glargine 100 U [iGlar]) plus lixisenatide) vs iGlar alone in patients with type 2 diabetes (T2D). To be included in the study, patients were required to be inadequately controlled on a regimen of basal insulin alone or in combination with 1 or2 oral glucose-lowering drugs. Efficacy was assessed for the following patient subgroups: A1C